You are here: Industry Insights > Bi

News List

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for CLL/SLL Patients in China PharmaSources
March 28, 2025
InnoCare announced the first patient dosed in the Phase III trial of ICP-248 combined with orelabrutinib for CLL/SLL. It's a potential treatment, with other trials advancing.
The Global Alpha-Glucosidase Inhibitor Market: Trends and Prospects David Orchard-Webb
March 18, 2025
Alpha-glucosidase inhibitors are used for type 2 diabetes. This article analyzes their market, including growth, segments, and challenges.
Is the Practice of "Prioritizing Biologics over Small Molecule Drugs" Justified? Krebs Qin
March 14, 2025
The article compares small molecule drugs and biologics in development, cost, etc., questions biologic - preferential policies, and mentions related acts for policy correction.
Microbiome Impact on Drug Response and Personalized Medicine Nurah Ekhlaque
February 18, 2025
The gut microbiome impacts drug response and disease management. It affects drug metabolism, efficacy, and toxicity, and is crucial for personalized medicine.
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China PharmaSources
February 18, 2025
InnoCare Pharma announced on Feb. 17, 2025 that CDE approved the Phase III trial of ICP - 248 combined with orelabrutinib for first - line CLL/SLL treatment in China.
The Role of Biosimilars Suzanne Elvidge
February 12, 2025
Biological drugs are therapeutics that are made by living organisms or are created from cells and tissues, and include therapeutic proteins and monoclonal antibodies.
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
Regenerative Medicine and Drug Development: The Intersection of Stem Cells and Biotech Nurah Ekhlaque
January 17, 2025
Explore how regenerative medicine and biotech are transforming drug development with stem cell therapies, personalised treatments, and innovative solutions.
HIV and the Antiretroviral Therapy Capsid Inhibitor Lenacapavir David Orchard-Webb
January 07, 2025
HIV is a major worldwide health issue, producing substantial morbidity and mortality.HIV targets the immune system, primarily CD4+ T cells, depleting them and making the body susceptible to opportunistic infections and malignancies.
China's Innovative Drugs Hunt for Billion Dollar Molecule Xiaobin
December 20, 2024
The Central Economic Work Conference in 2023 emphasized the need to promote industrial innovation through, especially by fostering new industries, new models, and new growth engines and developing new forms of productive forces.